A newly synthetic compound of Ibuprofen and Gabapentin as a novel analgesic and anti-inflammatory therapeutic agent: A pharmacological study in rats' experimental models.

Objective: Inflammation and pain are normally present concomitantly, which requires using a combination of anti-inflammatory and pain killer medications. This could potentially decrease patient adherence to such combinations. Therefore, there is an urgent need to develop combinations of antiinflammatory and analgesic therapies. This study is designed to evaluate the analgesic and antiinflammatory activities of a newly synthetic compound of ibuprofen and gabapentin. Method: The study protocol includes two stages. The first stage: the evaluation of the analgesic effectiveness of tested compounds via using hot plate and acetic acid induced-writhing tests. The second stage: the investigation of the anti-inflammatory activity via using dextran induced-peritonitis, cotton pelt induced-granulomas, and formalin induced-paw edema analyses. Rats were randomly divided into four groups (six rats in each group): Group A (control): rats were orally treated with vehicle (propylene glycol 50 % v/v); Group B: rats were orally treated with ibuprofen (10 mg/kg); Group C: rats were orally treated with gabapentin (200 mg/kg); and Group D: rats were orally treated with the synthetic compound (ibuprofen-gabapentin) in dose equivalent to 10 mg/kg ibuprofen and 200 mg/kg gabapentin. Result: It was found that the newly synthesized compound of ibuprofen and gabapentin has significantly reduced the pain in comparison with control groups. Additionally, this compound has significant anti-inflammatory properties compared to medications admitted to the control group as well. Conclusion: The newly synthesized compound (ibuprofen-gabapentin) demonstrates remarkable analgesic and anti-inflammatory activities in comparison with the conventional compounds. [ABSTRACT FROM AUTHOR]